MAVA | eMAX Health

From Insight to Action: Why Many Teams Stall at the Last Mile

Gathering insight is one thing. Acting on it fast enough to matter? That’s the real differentiator. Across pharma and biotech, manufacturers invest heavily in market access research—payer interviews, advisory panels, and data dashboards that reveal how coverage...

The Next Era of Advisory Panels: Blended Human + AI Moderation

Think advisory boards are still a once-a-year resort meeting? Think again. The next era is digital, iterative, and AI-assisted. The traditional advisory model involved flying in a dozen experts for a weekend of discussion and hoping insights would hold for a full...

MAVA in Action: Launch Strategy Shifted in Just 5 Days

Launch plans rarely survive first contact with payers. One immunology manufacturer learned this firsthand. Their internal strategy had a clear value story, aligned teams, and a rebate framework they believed would secure access. Then they tested it with MAVA®. Launch...

A New Federal Healthcare Advisory Committee: Implications for Pharma Market Access

The Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) recently announced the creation of a new Healthcare Advisory Committee—a body tasked with improving how care is financed and delivered under federal insurance...

Why Early Payer Validation Is Critical to Evidence Strategy in Market Access

As the market access landscape evolves, the bar for evidence is shifting. Payers aren’t looking for more data. They’re looking for the right data. They want real-world relevance, economic clarity, and justification that feels grounded in practice. Too often, HEOR...

« Older Entries

Next Entries »

From Insight to Action: Why Many Teams Stall at the Last Mile

The Next Era of Advisory Panels: Blended Human + AI Moderation

MAVA in Action: Launch Strategy Shifted in Just 5 Days

A New Federal Healthcare Advisory Committee: Implications for Pharma Market Access

Why Early Payer Validation Is Critical to Evidence Strategy in Market Access

Search by Category:

Recent Posts:

Search by Keyword:

From Insight to Action: Why Many Teams Stall at the Last Mile

The Next Era of Advisory Panels: Blended Human + AI Moderation

MAVA in Action: Launch Strategy Shifted in Just 5 Days

A New Federal Healthcare Advisory Committee: Implications for Pharma Market Access

Why Early Payer Validation Is Critical to Evidence Strategy in Market Access

Search by Category:

Recent Posts:

Search by Keyword:

Cookie Consent

Your Privacy Choices

Strictly Necessary (Always Active)

Analytics & Performance

Marketing & Advertising